Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 43

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 43
---
 851  
     1,358  
     159.6%
  
    PlaCCine Vaccine Program 
     -  
     2,554  
     (2,554) 
     -%
  
    Manufacturing (CMC) 
     746  
     1,551  
     (805) 
     (51.9)%
  
    Subtotal 
     2,955  
     4,956  
     (2,001) 
     (40.4)%
  
    Research and development expenses 
     5,291  
     9,407  
     (4,116) 
     (43.8)%
  
    General and administrative expenses 
     5,098  
     5,580  
     (482) 
     (8.6)%
  
    Total operating expenses 
     10,389  
     14,987  
     (4,598) 
     (30.7)%
  
    Loss from operations 
    $(10,389) 
    $(14,987) 
    $(4,598) 
     (30.7)%

30

Research
and Development Expenses

Research
and development (“R&D”) expenses were $5.3 million in the first nine months of 2025 compared to $9.4 million in same
period of 2024. Clinical costs associated with the OVATION 2 and MRD trials were $0.2 million in the first nine months of 2025 compared
to $1.1 million in 2024. Clinical costs associated with the OVATION 3 trial were $0.7 million in the first nine months of 2025. Clinical
costs associated with the PlaCCine vaccine trial were $42,000 in the first nine months of 2025 compared to $1.4 million in the first
nine months of 2024. Other clinical and regulatory costs were $1.4 million in the first nine months of 2025 compared to $1.9 million
in the same period of 2024. R&D costs associated with the development of IMNN-001 to support the OVATION program were $2.2 million
in the first nine months of 2025 compared to $0.9 million in same period of 2024. The cost of development